Skip to content
Research Article Open access CC BY 4.0

A Review of Covid-19 Detailed Study of History, Life Cycle, Diagnosis and Prevention of Corona Virus

J. Jeya Sheely

Asian Journal of Research in Infectious Diseases · pp. 50–61 · Published 1 Feb 2023

10.9734/ajrid/2023/v12i2241

Abstract

Coronavirus Disease-2019 is a new life-threatening, quickly-spreadable pandemic disease. It is a huge family of viruses known to cause sickness from breathing trouble, fever, fatigue, cough, sore throat, breathlessness, and common cold to the continuation of acute respiratory tract infection and the severity of the infection sometimes visible as pneumonia, acute respiratory syndrome and even death. The disease is commonly known as COVID-19. Since December 2019, Covid-19 emerged in Hunan seafood market at Wuhan in South China and rapidly spreading throughout the world, the virus epidemic has been proclaimed a public health emergency of International concern by World Health Organization (WHO). An exceedingly infectious potential for spreading resulted in the universal coronavirus disease 2019 (COVID-19) pandemic in 2020. Though some specialists cast doubts that the virus is transmitted from animals to humans, there are mixed results on the origin of coronavirus. In this review, we go through the history of covid-19, virus life cycle, diagnosis, and prevention with reference to the historical coronavirus pandemic in 2002.

COVID-19 SARS symptoms respiratory syndrome treatment

References (66)

  1. 1 Clinical Characteristics of Coronavirus Disease 2019 in China [DOI]
  2. 2 Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China [DOI]
  3. 3 Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia [DOI]
  4. 4 A new coronavirus associated with human respiratory disease in China [DOI]
  5. 5 The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application [DOI]
  6. 6 Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia [DOI]
  7. 7 Detection of SARS-CoV-2 in Different Types of Clinical Specimens [DOI]
  8. 8 Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome [DOI]
  9. 9 A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome [DOI]
  10. 10 Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study [DOI]
  11. 11 Coronavirus as a possible cause of severe acute respiratory syndrome [DOI]
  12. 12 A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong [DOI]
  13. 13 Bats Are Natural Reservoirs of SARS-Like Coronaviruses [DOI]
  14. 14 Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome [DOI]
  15. 15 Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China [DOI]
  16. 16 The Genome Sequence of the SARS-Associated Coronavirus [DOI]
  17. 17 Chloroquine is a potent inhibitor of SARS coronavirus infection and spread [DOI]
  18. 18 Diagnosing COVID-19: The Disease and Tools for Detection [DOI]
  19. 19 Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats [DOI]
  20. 20 The Severe Acute Respiratory Syndrome [DOI]
  21. 21 From SARS to MERS, Thrusting Coronaviruses into the Spotlight [DOI]
  22. 22 Identification of Severe Acute Respiratory Syndrome in Canada [DOI]
  23. 23 Lung pathology of fatal severe acute respiratory syndrome [DOI]
  24. 24 Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples [DOI]
  25. 25 Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome [DOI]
  26. 26 Responding to global infectious disease outbreaks: Lessons from SARS on the role of risk perception, communication and management [DOI]
  27. 27 In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine [DOI]
  28. 28 Saliva is a reliable tool to detect SARS-CoV-2 [DOI]
  29. 29 Diagnostic Testing for Severe Acute Respiratory Syndrome–Related Coronavirus 2 [DOI]
  30. 30 Treatment of SARS with human interferons [DOI]
  31. 31 Comparison of seven commercial RT-PCR diagnostic kits for COVID-19 [DOI]
  32. 32 Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection [DOI]
  33. 33 Comparative Performance of SARS-CoV-2 Detection Assays Using Seven Different Primer-Probe Sets and One Assay Kit [DOI]
  34. 34 COVID-19 diagnostics in context [DOI]
  35. 35 Clinical presentations and outcome of severe acute respiratory syndrome in children [DOI]
  36. 36 SARS-CoV Infection in a Restaurant from Palm Civet [DOI]
  37. 37 In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends [DOI]
  38. 38 Taking connected mobile-health diagnostics of infectious diseases to the field [DOI]
  39. 39 Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources [DOI]
  40. 40 Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system [DOI]
  41. 41 An alternative workflow for molecular detection of SARS-CoV-2 – escape from the NA extraction kit-shortage, Copenhagen, Denmark, March 2020 [DOI]
  42. 42 Interferon-β 1a and SARS Coronavirus Replication [DOI]
  43. 43 Nasal Swab Sampling for SARS-CoV-2: a Convenient Alternative in Times of Nasopharyngeal Swab Shortage [DOI]
  44. 44 Clinical Evaluation of the cobas SARS-CoV-2 Test and a Diagnostic Platform Switch during 48 Hours in the Midst of the COVID-19 Pandemic [DOI]
  45. 45 A Patient with Asymptomatic Severe Acute Respiratory Syndrome (SARS) and Antigenemia from the 2003–2004 Community Outbreak of SARS in Guangzhou, China [DOI]
  46. 46 Comparison of Two High-Throughput Reverse Transcription-PCR Systems for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2 [DOI]
  47. 47 Severe Acute Respiratory Syndrome Coronavirus 3a Protein Is a Viral Structural Protein [DOI]
  48. 48 Quantification of individual subgenomic mRNA species during replication of the coronavirus transmissible gastroenteritis virus [DOI]
  49. 49 The COVID‐19 epidemic [DOI]
  50. 50 Assay Techniques and Test Development for COVID-19 Diagnosis [DOI]
  51. 51 SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis [DOI]
  52. 52 Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT–qPCR primer–probe sets [DOI]
  53. 53 Rapid spread of the SARS-CoV-2 Delta variant in some French regions, June 2021 [DOI]
  54. 54 Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021 [DOI]
  55. 55 Molecular diagnostic technologies for COVID-19: Limitations and challenges [DOI]
  56. 56 Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs [DOI]
  57. 57 A Recurrent Mutation at Position 26340 of SARS-CoV-2 Is Associated with Failure of the E Gene Quantitative Reverse Transcription-PCR Utilized in a Commercial Dual-Target Diagnostic Assay [DOI]
  58. 58 Comparison of Unsupervised Home Self-collected Midnasal Swabs With Clinician-Collected Nasopharyngeal Swabs for Detection of SARS-CoV-2 Infection [DOI]
  59. 59 Extraction-free SARS-CoV-2 detection by rapid RT-qPCR universal for all primary respiratory materials [DOI]
  60. 60 Clinical and Laboratory Diagnosis of SARS-CoV-2, the Virus Causing COVID-19 [DOI]
  61. 61 Fast SARS-CoV-2 detection by RT-qPCR in preheated nasopharyngeal swab samples [DOI]
  62. 62 Clinical Samples for SARS-CoV-2 Detection: Review of the Early Literature [DOI]
  63. 63 Nucleic Acid and Immunological Diagnostics for SARS-CoV-2: Processes, Platforms and Pitfalls [DOI]
  64. 64 Comparison of 12 Molecular Detection Assays for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [DOI]
  65. 65 COVID-19 paraclinical diagnostic tools: Updates and future trends [DOI]
  66. 66 A case of gastrointestinal‐predominant COVID‐19 demonstrates value of stool PCR test [DOI]

Cited by 1

Generating Novel Small Molecule Drugs for Selected SARS-CoV-2 Proteins: The Medgnosis GenAI Approach

Autogon Inc. 3002 Falls at Fairdale, 77057, USA, E.O Obi, J.A. Yentumi · Advances in Multidisciplinary & Scientific Research Journal Publication · 2024

Related research

Article metrics

Real usage data collected on this platform.

50

Page views

0

PDF downloads

22

Outbound clicks

1

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.